A Phase 1 interventional study of MEDI4736 and tremelimumab in Advanced Solid Tumors, sponsored by MedImmune LLC. Completed at 75 sites in 9 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2020-03-06.
Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a multicenter, open-label, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, PK and immunogenicity of MEDI4736 in combination with tremelimumab in subjects with select advanced solid tumors.
MedImmune LLC is the lead sponsor of 270 studies on the registry; none are open to participants now.
Of its 52 completed or terminated interventional studies of FDA-regulated products, 29 (56%) have results posted.
First submitted after MedImmune LLC became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with multiple tumor types.
Biological: MEDI4736 · Biological: tremelimumab
MEDI4736 is administered by IV infusion in combination with tremelimumab
Tremelimumab is administered by IV infusion in combination with MEDI4736
Number of subjects reporting adverse events
Time frame: Screening through 15 months after the last subject enters re-treatment
Number of subjects reporting serious adverse events
Time frame: Screening through 15 months after the last subject enters re-treatment
Number of subjects experiencing a dose-limiting toxicity
Time frame: First dose of study medication through 4 weeks after the first dose of study medication
Change from Baseline in laboratory evaluations
Time frame: Screening through 3 months after the last dose of study medication
Change from Baseline in vital signs
Time frame: Screening through 3 months after the last dose of study medication
Change from Baseline in electrocardiogram evaluations
Time frame: Screening through 3 months after the last dose of study medication
Overall Response Rate in Select Tumor Types
Time frame: First dose of study medication through 15 months after the last subject enters re-treatment
Overall Response Rate
Time frame: First dose of study medication through 15 months after the last subject enters re-treatment
Disease Control Rate
Time frame: First dose of study medication through 15 months after the last subject enters re-treatment
Duration of Response
Time frame: First dose of study medication through 15 months after the last subject enters re-treatment
Progression-Free Survival
Time frame: First dose of study medication through 15 months after the last subject enters re-treatment
Overall Survival
Time frame: First dose of study medication through 15 months after the last subject enters re-treatment
Individual MEDI4736 concentrations
Time frame: First dose of MEDI4736 through 3 months after the last dose of study medication
Individual tremelimumab concentrations
Time frame: First dose of tremelimumab through 3 months after the last dose of study medication
MEDI4736 area under the concentration-curve
Time frame: First dose of MEDI4736 through 3 months after the last dose of study medication
Tremelimumab area under the concentration-curve
Time frame: First dose of tremelimumab through 3 months after the last dose of study medication
Number of subjects that develop detectable antidrug antibodies to MEDI4736
Time frame: First dose of MEDI4736 through 3 months after the last dose of study medication
Number of subjects that develop antidrug antibodies to tremelimumab
Time frame: First dose of tremelimumab through 3 months after the last dose of study medication
Change in Biomarkers
Time frame: Screening through 3 months following the last dose of study medication
Ran from Oct 2014 to primary completion in Jan 2020, 63 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Durvalumab · Tremelimumab